Build with KISHO Sign In Sign Up

Kisho

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company — Rare Disease Pipeline | Kisho | Kisho

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company

Other

4

Orphan Designations

0

FDA Approvals

15

Rare Diseases

0

News Articles

Disease	Drug(s)	Designation	Approved
RET fusion positive cancer	RETEVMORetevmo	Orphan Designation	-
adult neuronal ceroid lipofuscinosis	Jaypirca	Orphan Designation	-
adult pleomorphic rhabdomyosarcoma	JaypircaRetevmo	Orphan Designation	-
adult-onset non-insulinoma persistent hyperinsulinemic hypoglycemia	RetevmoJaypirca	Orphan Designation	-
adult-onset proximal spinal muscular atrophy, autosomal dominant	Jaypirca	Orphan Designation	-
autosomal dominant myopia-midfacial retrusion-sensorineural hearing loss-rhizomelic dysplasia syndrome	RETEVMO	Orphan Designation	-
chronic lymphocytic leukemia/small lymphocytic lymphoma	Jaypirca	Orphan Designation	-
familial scaphocephaly syndrome, McGillivray type	RETEVMORetevmo	Orphan Designation	-
micrognathia-recurrent infections-behavioral abnormalities-mild intellectual disability syndrome	RETEVMORetevmo	Orphan Designation	-
muscle tissue disorder	Retevmo	Orphan Designation	-
primary adult heart tumor	JaypircaRetevmo	Orphan Designation	-
soft tissue amyloid neoplasm	Retevmo	Orphan Designation	-
soft tissue chondroma	Retevmo	Orphan Designation	-
soft tissue sarcoma	Retevmo	Orphan Designation	-
tumor of adipose tissue	Retevmo	Orphan Designation	-

← Back to Companies